Revolutionizing Cancer Therapy With Transport Oncophysics
Our Mission Is to Be the First to Develop Fully Curative Approaches to Metastatic Cancer.
We are focused on developing drugs for the prevention, treatment, and cure of metastatic cancers using nanoporous silicon microparticles.
Unprecedented Efficacy
Unprecedented efficacy in treating metastatic cancer has been demonstrated in preclinical trials.
Peer-reviewed Research
Our research has been published in leading peer-reviewed scientific journals.
Patent Protected
Protected by strong patent portfolio with technology licensed from Houston Methodist Research Institute & University of Texas Health Science Center at Houston.
About Us
BrYet Europe srl is the European branch of BrYet US Inc., a privately-owned biotech company focused on the discovery and development of novel physics-based, first-in-class therapies for metastatic liver and lung cancers.
Technology
Learn more about our research and technology.
News
Catch up on the latest news and more from BrYet.
Contact Us
Reach out for more information.